ONO-3403

• UNSPSC Description:

  ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors[1][2][3][4].

• Target Antigen:

  Apoptosis; Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ono-3403.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=C(C=C1)/C=C(C(N(CC=C)CC(OCC)=O)=O)\C)OC2=CC=C(C=C2)C(N)=N.CS(=O)(O)=O

• Molecular Weight:

  545.60

• References & Citations:

  [1]Tumurkhuu G, et al. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 2011;17(1):97-105.|[2]Hiwasa T, et al. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 1998;126(2):221-225.|[3]Ohkoshi M, et al. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res. 2002;22(2A):821-823.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  181586-07-2